Once-a-day extended-release dosage form of divalproex sodium III: Development and validation of a level A in vitro-in vivo correlation (IVIVC)

Journal of Pharmaceutical Sciences

Volumn 94, Issue 9, 2005, Pages 1949-1956

  Dutta, Sandeep ^a   Qiu, Yihong ^a   Samara, Emil ^a,b   Cao, Guoliang ^a,c   Granneman, G Richard ^a  

^a ABBOTT LABORATORIES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Controlled release; Dissolution; in vitro in vivo correlations (IVIVC); Matrix formulation; Modified release; Pharmacokinetics

Indexed keywords

FILLER; HYDROXYPROPYLMETHYLCELLULOSE; LUBRICATING AGENT; VALPROATE SEMISODIUM; VALPROIC ACID;

ARTICLE; BIOEQUIVALENCE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MATRIX TABLET; NORMAL HUMAN; PREDICTION; QUANTITATIVE ANALYSIS; RELIABILITY; SINGLE DRUG DOSE; TABLET FORMULATION; VALIDATION PROCESS;

EID: 27644563437     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20387     Document Type: Article

References (13)

1. Skelly JP, Barr WH, Benet LZ, Doluisio JT, Goldberg AH, Levy G, Lowenthal DT, Robinson JR, Shah VP, Temple RJ, Yacobi A. 1987. Report of the workshop on controlled-release dosage forms: Issues and controversies. Pharm Res 4:75-77.
2. Pharmacopeial Forum. 1988. In vitro-in vivo correlation for extended-release oral dosage forms. 14:4160-4161.
3. Skelly JP, Shiu GF. 1993. In vitro/in vivo correlations in biopharmaceutics: Scientific and regulatory implications. Eur J Drug Metab Pharmacokinet 18:121-129.
4. Siewert W. 1993. Perspectives of in vitro dissolution tests in establishing in vitro/in vivo correlations. Eur J Drug Metab Pharmacokinet 18:7-18.
5. Skelly JP, Amidon GL, Barr WH, Benet LZ, Carter JE, Robinson JR, Shah VP, Yacobi A. 1990. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharm Res 7:975-982.
6. Khan MZ. 1996. Dissolution testing for sustained or controlled-release oral dosage forms and correlation with in vivo data: Challenges and opportunities. Int J Pharm 140:131-143.
7. Food and Drug Administration. 1997. Guidance for industry, extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations.
8. Qiu Y. 2005. Design and application of predictive in vitro tests for in vitro-in vivo correlations of oral extended-release dosage forms. Am Pharm Rev (in press).
9. Qiu Y, Cheskin HS, Engh KR, Poska RP. 2003. Once-a-day controlled-release dosage form of divalproex sodium I: Formulation design and in vitro/in vivo investigations. J Pharm Sci 92:1166-1173.
10. Depakote® Tablet. 2003. Physicians' desk reference.
11. Qiu Y, Garren J, Samara E, Cao G, Abraham C, Cheskin HS, Engh KR. 2003. Once-a-day controlled-release dosage form of divalproex sodium II: Development of a predictive in vitro release method. J Pharm Sci 92:2317-2325.
12. Cavanaugh JH, Hussein Z, Lamm J, Granneman GR. 1994. Pharmacokinetics of multiple oral dose divalproex sodium after intravenous loading dose administration in healthy volunteers. Drug Invest 7:1-7.
13. Beal S, Sheiner L. 1998. NONMEM, Version V 1.1; ed. N.P. Group. San Francisco.